Genomic Vision Receives EUR 473,000 Boost to Technology Development Program
News Jan 30, 2007
Genomic Vision announces the certification and financing of two of its R&D projects by two organizations involved in oncology.
The certification of two of its projects by Medicen Paris-Region and France's National Cancer Institute (INCa - Institut National du Cancer) means that Genomic Vision will be able to complete the technical developments required for the use of its molecular combing technology for early cancer diagnosis within two years and also to widen the oncology applications of the technology.
The first Genomic Vision R&D project, Cancer Diagnosis using Molecular Combing, has been certified by INCa as part of its innovation in cancer initiative. As a result, the company will receive EUR 180,000.
The second R&D project for which Genomic Vision will receive certification and financing is Biotype, under the auspices of Medicen. The Ile de France Regional Council is contributing EUR 1.7 million to Biotype. Out of this, Genomic Vision will receive EUR 293,000.
"Genomic Vision's goal is to extend the use of our molecular combing technology diagnostic tools to hospitals after achieving widespread presence in research labs," said Aaron Bensimon, founder, president and CEO of Genomic Vision.
"Thanks to our investors and these two new grants, we will be able to concentrate on the development of our technology for routine diagnostic applications."
The Cancer Diagnosis using Molecular Combing project is aimed at providing proof of concept for early diagnosis of cancer by analyzing re-arrangement of genes in genomic regions representing great distances. Achieving this goal will entail technical optimization to overcome constraints specific to this type of diagnosis, and also the validation of these developments on the chosen pathologies.
Genomic Vision expects the project to lead to the opening up of various applications of molecular combing in oncology, such as diagnostics, discovery of cancer drugs and pharmacogenomics.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.